Segmented Cardiovascular Capsule for Customizable Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical technologies face challenges in creating customizable combinations of acetylsalicylic acid, HMG-CoA reductase inhibitors, and ACE inhibitors at fixed doses for cardiovascular disease prevention, which are difficult to adapt to individual patient needs due to dosage complexity and manufacturing costs.
Innovation Solution
Development of capsules containing variable numbers of acetylsalicylic acid, HMG-CoA reductase inhibitor, and ACE inhibitor tablets, with customizable dosing and protective coatings to prevent degradation and incompatibility, allowing for easy scaling and individualized treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple drugs are combined in fixed-dose formulations, then treatment effectiveness is improved, but dosage complexity increases
Solution Approach 1:
The patent divides the combination therapy into separate tablets, each containing a different drug (acetylsalicylic acid, HMG-CoA reductase inhibitor, and ACE inhibitor). These segmented tablets are then combined in a single capsule, allowing flexible customization of the number and type of tablets to match individual patient needs while maintaining the benefits of combination therapy.
Solution Approach 2:
The patent enables dynamic adjustment of the dosage regimen by allowing different numbers of tablets of each type to be placed in the capsule based on the patient's specific condition, age, and risk factors. This dynamic customization resolves the contradiction by adapting the fixed-dose combination to individual patients without increasing overall system complexity.
2Ease of operation
If multiple drugs are combined in a single formulation, then compliance is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the combination therapy into separate manufacturable units (individual tablets) that can be produced using standard manufacturing processes. These segmented tablets are then assembled into capsules in flexible ratios, simplifying manufacturing compared to creating entirely new fixed-dose combination formulations while still improving compliance through single-capsule administration.
Solution Approach 2:
The patent creates a universal capsule system that can accommodate different numbers and types of tablets based on patient needs. This multi-functional approach allows the same capsule platform to serve multiple dosing regimens, improving compliance without requiring complex manufacturing processes for each specific combination.
3Volume of stationary object
If drugs are placed in direct contact, then capsule size is reduced, but drug incompatibility increases
Solution Approach 1:
The patent uses separate tablets for each drug, which physically segment the drugs and prevent direct contact. Each tablet acts as an isolated compartment, eliminating drug incompatibility issues while maintaining a compact capsule size through the efficient use of tablet-based segmentation.
4Adaptability or versatility
If customizable dosing is implemented, then adaptability to individual patients is improved, but device complexity increases
Solution Approach 1:
The patent achieves customizable dosing through segmentation of the therapy into separate tablets that can be selectively combined in the capsule. This segmentation allows flexible adaptation to individual patient needs without requiring complex capsule structures, as the customization is achieved through simple variation in the number of tablets of each type.
Data Source
Figure 1
AI summary
The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.